The company ModernaTX, Inc is enrolling patients into the clinical trial investigating A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age.
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition,mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
The study start date is October 10, 2022.
The patients that can be enrolled into this study include a female or male 9 to 15 years of age or is a female 16 to 25 years of age at the time of consent, who are in good general health and is capable of complying with study procedures. Whereas, for the CMV-seronegative cohorts: at the Screening visit, a participant is CMV IgG-negative and CMV immunoglobulin M (IgM)-negative, and for CMV-seropositive cohorts, a participant is CMV IgG-positive and CMV IgM-negative, CMV IgG-positive and CMV IgM-positive, or CMV IgG-positive and CMV IgM-indeterminate.
This page provides a more detailed overview of this clinical trial, icluding the exclusion and inclusion criteria in detail, and the investigational sites locations and contact details: https://ichgcp.net/clinical-trials-registry/NCT05575492.